0000000000349250

AUTHOR

Thomas Discher

showing 4 related works from this author

Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance‐associated substitutions

2020

Background&aims The presence of baseline resistance-associated substitutions (RASs) reduced sustained virologic response (SVR) rates in chronic hepatitis C virus (HCV) genotype 1a infected patients treated with Elbasvir/Grazoprevir (EBR/GZR). This study aimed to evaluate the frequency of NS5A RASs and treatment outcomes in patients for whom EBR/GZR was intended. Methods We sequenced NS5A in 832 samples from German genotype1a-infected DAA-naive patients population-based, which were collected in the European Resistance Database. Treatment outcomes and clinical parameters were evaluated in 519 of these patients retrospectively. Results Overall, 6.5% of patients harbored EBR-specific NS5A RASs …

medicine.medical_specialtyElbasvirHepatologybusiness.industryHepatitis C virusTreatment outcomemedicine.disease_causeGastroenterology03 medical and health sciences0302 clinical medicineGenotype 1bGrazoprevir030220 oncology & carcinogenesisInternal medicineHepatitis C virus genotypeMedicine030211 gastroenterology & hepatologyIn patientbusinessNS5ALiver International
researchProduct

Sexual Health in HIV-Positive Men Under Stable Antiretroviral Therapy During a 12-Month Period

2021

Sexual health is becoming increasingly important for many HIV-positive men undergoing highly effective antiretroviral therapy (ART) but remains frequently unaddressed in routine clinical consultation.To comprehensively evaluate sexual health in male patients with HIV on stable ART over a 12-month period.The prospectively registered cohort study comprising 87 HIV-positive men on stable ART (median age: 43 years) was conducted between 2011 and 2015 at a university hospital. Patients were enrolled from the outpatient infectious disease unit and underwent an extensive andrological workup to assess parameters of sexual health (questionnaires, sex hormones, ultrasound, 2-glass urine test includin…

AdultMalePediatricsmedicine.medical_specialtySexual BehaviorUrologyEndocrinology Diabetes and MetabolismSexually Transmitted Diseases030232 urology & nephrologyHIV InfectionsCohort Studies03 medical and health sciencesSemen quality0302 clinical medicineEndocrinologyClinical endpointHumansMedicineChildReproductive health030219 obstetrics & reproductive medicinebusiness.industrymedicine.diseasePsychiatry and Mental healthSexual PartnersSexual dysfunctionErectile dysfunctionReproductive MedicineCohortSexual Healthmedicine.symptombusinessViral loadCohort studyThe Journal of Sexual Medicine
researchProduct

Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric di…

2012

BACKGROUND: Depression is a major complication during treatment of chronic hepatitis C virus (HCV) infection with interferon-alpha (IFN-alpha). It is unclear whether antidepressants can prevent IFN-induced depression in patients without psychiatric risk factors. OBJECTIVE: To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-alpha in HCV-infected patients without a history of psychiatric disorders. DESIGN: Randomized, multicenter, double-blind, prospective, placebo-controlled, parallel-group trial. (ClinicalTrials.gov registration number: NCT00136318) SETTING: 10 university and 11 academic…

medicine.medical_specialtyPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineInternal MedicinemedicineEscitalopram030212 general & internal medicinePsychiatryDepression (differential diagnoses)business.industryIncidence (epidemiology)Absolute risk reductionGeneral MedicineHepatitis Cmedicine.disease3. Good healthTolerability030211 gastroenterology & hepatologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Influence of gender on cytokine induced depression and treatment

2021

Abstract Background Cytokine treatment with Interferon-alpha (IFN-α) represents a clinical model of immune associated depression, but it remains unclear if it is of the same entity as major depressive disorder (MDD). The study focuses on possible gender differences in IFN-α induced depression and effects of a pre-emptive antidepressant treatment. Methods Data from 181 patients with chronic hepatitis C infection (cHC) without history of mental illnesses undergoing treatment with IFN-α 2a and ribavirin were re-analyzed for gender effects. Patients with a pre-emptive antidepressant therapy with Escitalopram (n = 90, verum group) to prevent IFN-induced depression were compared to patients who r…

medicine.medical_specialtyHamilton Anxiety Rating Scalebusiness.industryAlpha interferonmedicine.diseasePlacebo030227 psychiatry03 medical and health sciencesPsychiatry and Mental healthClinical Psychology0302 clinical medicineRating scaleInternal medicinemedicineMajor depressive disorderAntidepressantEscitaloprambusiness030217 neurology & neurosurgeryDepression (differential diagnoses)medicine.drugJournal of Affective Disorders
researchProduct